# Journal Pre-proof

High-dose vitamin D3 supplementation in pregnancy and risk of neurodevelopmental disorders in the children at age 10 - A randomized clinical trial

Kristina Aagaard, MD, Jens Richardt Møllegaard Jepsen, MSc PhD, Astrid Sevelsted, MSc PhD, David Horner, MSc MD, Rebecca Vinding, MD PhD, Julie Bøjstrup Rosenberg, MD, Nicklas Brustad, MD PhD, Anders Eliasen, MSc PhD, Parisa Mohammadzadeh, MD, Nilofar Følsgaard, MD PhD, María Hernández-Lorca, MSc PhD, Birgitte Fagerlund, Birte Y. Glenthøj, MD DMSc, Morten Arendt Rasmussen, MSc PhD, Niels Bilenberg, MD PhD, Jakob Stokholm, MD PhD, Klaus Bønnelykke, MD PhD, Bjørn H. Ebdrup, MD PhD, Bo Chawes, MD PhD DMSc

PII: S0002-9165(23)66298-7

DOI: https://doi.org/10.1016/j.ajcnut.2023.12.002

Reference: AJCNUT 387

To appear in: *The American Journal of Clinical Nutrition*

Received Date: 2 July 2023

Revised Date: 28 November 2023

Accepted Date: 4 December 2023

Please cite this article as: K. Aagaard, J.R. Møllegaard Jepsen, A. Sevelsted, D. Horner, R. Vinding, J.B. Rosenberg, N. Brustad, A. Eliasen, P. Mohammadzadeh, N. Følsgaard, M. Hernández-Lorca, B. Fagerlund, B.Y. Glenthøj, M.A. Rasmussen, N. Bilenberg, J. Stokholm, K. Bønnelykke, B.H. Ebdrup, B. Chawes, High-dose vitamin D3 supplementation in pregnancy and risk of neurodevelopmental disorders in the children at age 10 - A randomized clinical trial, *The American Journal of Clinical Nutrition*, https://doi.org/10.1016/j.ajcnut.2023.12.002.

# High-dose vitamin D3 supplementation in pregnancy and risk of neurodevelopmental disorders in the children at age 10 - A randomized clinical trial

Kristina Aagaard MD (1), Jens Richardt Møllegaard Jepsen MSc PhD (2+3), Astrid Sevelsted MSc PhD (1), David Horner MSc MD (1), Rebecca Vinding MD PhD (1), Julie Bøjstrup Rosenberg MD (1+3), Nicklas Brustad MD PhD (1), Anders Eliasen MSc PhD (1+4), Parisa Mohammadzadeh MD (1+3), Nilofar Følsgaard MD PhD (1), María Hernández-Lorca MSc PhD (1), Birgitte Fagerlund (2+3+5), Birte Y. Glenthøj MD DMSc (3+6), Morten Arendt Rasmussen MSc PhD (1+7), Niels Bilenberg MD PhD (8+9), Jakob Stokholm MD PhD (1+7), Klaus Bønnelykke MD PhD (1+6), Bjørn H. Ebdrup MD PhD (3+6)*, and Bo Chawes MD PhD DMSc (1+6)*

1) Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Gentofte, Denmark
2) Child and Adolescent Mental Health Center, Copenhagen University Hospital - Mental Health Services CPH, Copenhagen, Denmark
3) Center for Neuropsychiatric Schizophrenia Research (CNSR) & Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), Mental Health Centre Glostrup, University of Copenhagen, Glostrup, Denmark
4) Department of Health Technology, Section for Bioinformatics, Technical University of Denmark
5) Department of Psychology, University of Copenhagen, Copenhagen, Denmark
6) Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
7) Section of Food, Microbiology and Fermentation, Department of Food Science, University of Copenhagen
8) Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
9) Department of Child and Adolescent Mental Health Odense, Mental Health Services in the Region of Southern Denmark, University of Southern Denmark, Odense, Denmark
*Contributed equally

**Correspondence to:** Bo Chawes. E-mail: chawes@copsac.com
**Word count: 3324**
**Trial registration:** Identifier: NCT00856947.
URL:
https://classic.clinicaltrials.gov/ct2/show/NCT00856947?term=NCT00856947&draw=2&rank=1
**Data Share Statement:** Data described in the manuscript, code book, and analytic code will be made available upon request pending approval by author Klaus Bønnelykke (kb@copsac.com) and a signed data access agreement.

**Abbreviations:**

ADHD: Attention deficit hyperactivity disorder

ADHD-RS: ADHD-Rating Scale

CARS: Childhood Autism Rating Scale

COPSAC: Copenhagen Prospective Studies on Asthma in Childhood

COPSYCH: COpenhagen Prospective Study on Neuro-PSYCHiatric Development

ICD-10: the International Classification of Disorders 10$^{th}$ Revision

IU: International Units

K-SADS-PL: Kiddie-Schedule for Affective Disorders and Schizophrenia for School-Age Children - Present and Lifetime Version

MCA: Multiple correspondence analysis

MRI: Magnetic resonance imaging

nmol/L: Nanomoles Per Liter

n-3 LCPUFA: Omega-3 long-chain polyunsaturated acids

RCT: Randomized clinical trial

SRS-2: Social Responsiveness Scale 2

25(OH)D: 25-hydroxy-vitamin D

# ABSTRACT

**Background:** Vitamin D deficiency in pregnancy may increase risk of autism and attention deficit hyperactivity disorder (ADHD).

**Objective:** To estimate the effect of vitamin D3 supplementation in pregnancy on risk of autism and ADHD.

**Design:** This randomized clinical trial was part of the COpenhagen Prospective Study on Neuro-PSYCHiatric Development (COPSYCH) project nested within the Copenhagen Prospective Studies on Asthma in Childhood 2010 (COPSAC2010) cohort comprising a population-based sample of 700 healthy mother-child pairs enrolled at week 24 of pregnancy. Maternal 25-hydroxy-vitamin D (25(OH)D) was measured at inclusion and 623 mothers were randomized 1:1 to either high-dose (2800 IU/d) or standard-dose (400 IU/d) vitamin D3 until 1 week postpartum (315 received high-dose, 308 standard dose). At age 10, diagnoses and symptom load of autism and ADHD, respectively, were established using the Kiddie-Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL).

**Results**: 591 children completed the psychopathological evaluation at age 10, sixteen children (2.7%) were diagnosed with autism and 65 (11.0%) with ADHD. Hereof, 496 children participated in the vitamin D3 trial (246 received high-dose, 250 standard dose). Of these, twelve children (2.4%) were diagnosed with autism and 58 (11.7%) with ADHD. Higher maternal pre-intervention 25(OH)D levels were associated with a decreased risk of autism (OR per 10 nmol/L 0.76 (0.59,0.97), p=0.034)), lower autistic symptom load (β per 10 nmol/L -0.03 (-0.05,0.00), p=0.024), and decreased risk of ADHD diagnosis (OR per 10 nmol/L 0.88 (0.78,0.99), p=0.033). High-dose vitamin D3 supplementation was not associated with risk of autism or ADHD.

**Conclusions:** Higher maternal pre-intervention 25(OH)D was associated with a decreased risk of autism, lower autistic symptom load, and decreased risk of ADHD diagnosis, but high-dose vitamin D3 supplementation in pregnancy had no effect on risk of autism and ADHD.

**Trial registration:** ClinicalTrials.gov Identifier: NCT00856947

**Key words:** Vitamin D, Autism, ADHD, neurodevelopment, supplementation

# INTRODUCTION

During fetal development, the brain undergoes rapid growth and development. Early environmental exposures during this vulnerable phase may have long term consequences including affected risk of common neurodevelopmental disorders, such as autism and attention deficit hyperactivity disorder (ADHD).(1,2)

The prevalence of vitamin D deficiency in pregnancy has globally been estimated to be present in above 50% of pregnant women.(3) Animal models have shown that vitamin D is crucial for the developing brain, as it contributes to functions including modulation of neurotransmission and neuroprotection.(4,5) Since the fetus relies on vitamin D passing from the mother through the placenta, maternal vitamin D deficiency may potentially affect fetal brain development.(6)

Previous observational studies have reported that maternal vitamin D deficiency in pregnancy is associated with the risk of autism and ADHD in the offspring, however, results are ambiguous, and potentially confounded by diet, lifestyle and season.(7–15) Further, lower gestational vitamin D has been shown to increase the severity of traits and symptoms of autism and ADHD in childhood in some studies(7,8,16–19), but not in other.(20–23) However, no randomized clinical trials (RCTs) of vitamin D supplementation in pregnancy have investigated the effect on neurodevelopmental disorders.

Based on a hypothesized protective effect of higher serum vitamin D in pregnancy, we investigated the effect of high compared with. standard-dose of vitamin D3 supplementation in an RCT in third trimester of pregnancy on the risk of autism and ADHD and corresponding

symptom load evaluated clinically at age 10 as part of the COpenhagen Prospective Study on Neuro-PSYCHiatric Development (COPSYCH) project.(24)

# METHODS

## Study Design

The COPSYCH project is nested within the Copenhagen Prospective Studies on Asthma in Childhood 2010 (COPSAC2010) cohort comprising 700 mother-child pairs enrolled at week 24 of pregnancy. Pregnant women living in Zealand (Latitude 55° N), Denmark, were recruited by a written invitation sent out after their first pregnancy visit at the general physician. Women not fluent in Danish, with an intake of more than 600 IU vitamin D3 per day, and/or with any kidney, heart, or endocrine disorder were excluded. From the COPSAC2010 cohort, 623 pregnant women were included in the vitamin D3 trial. The offspring were followed prospectively and deeply phenotyped at the COPSAC unit through 14 visits until age 10.(25) At age 10 the children underwent an extensive neuropsychiatric evaluation. Children with a birth weight below 1500g or a gestational age below 28 weeks were excluded from analyses.(1,2) For further details see Supplementary Material.

The study was conducted according to the guiding principles of the Declaration of Helsinki and was approved by the Local Ethics Committee (H-B-2009-014, COPSAC2010: H-B-2008-093), and the Danish Data Protection Agency (COPSAC2010: 2015-41-3696). All study participants provided informed consent.

## Vitamin D intervention

The pregnant women were randomized 1:1 to a daily vitamin D3 supplementation of 2400 IU or placebo starting from the first visit at the COPSAC research unit at week 24 of pregnancy until 1 week postpartum. The vitamin D3 intervention was performed between March 4, 2009, and November 17, 2010. An external investigator with no additional involvement in the RCT performed the randomization by a computer-generated list of random numbers. All included women were instructed to continue a daily vitamin D3 supplementation of 400 IU throughout pregnancy as recommended by the Danish National Board of Health. Total supplementation was therefore 2800 IU/d Vitamin D3 in the intervention (high-dose) group and 400 IU/d in the control (standard-dose) group. Mothers were asked to return capsules after the intervention period to estimate the adherence. The study was double-blinded until the youngest child had reached the age of 3 years, with the exception of medical emergency (3 cases of early unblinding). From this age information on treatment group was available to all parents. In a factorial 2x2 design, pregnant women were simultaneously randomized to a daily fish oil (n-3 LCPUFA) supplement of 2400 mg or olive oil capsules (ClinicalTrials.gov: NCT00798226).(25)

## Serum measures of 25(OH)D

Maternal serum 25(OH)D levels were measured pre- and post-intervention at week 24 of pregnancy and 1 week post-partum respectively. Child serum 25(OH)D levels were measured at 6 months and 6 years.(26)

## The COPSYCH 10-year visit

The COPSYCH 10-year clinical visit was a post hoc follow-up of the vitamin D3 RCT (ClinicalTrials.gov Identifier: NCT00856947). The visit was carried out over 2 days and included an extensive evaluation of psychopathology, neurocognition, and brain structure and function using magnetic resonance imaging (MRI).(24) Examinations were carried out between January 2019 and December 2021. Categorical psychopathology was established by use of the semi-structured clinical diagnostic interview Kiddie-Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL).(27) All K-SADS-PL interviews were administered by trained medical doctors, nurses, and psychologists and were video recorded to enable supervision by a psychologist (JRJM) and for external validation diagnostic conferences with a clinical professor of child and adolescent psychiatry (NB) both specialists in child and adolescent psychiatry to reach consensus on diagnostics.(24) Clinician verified symptom load of psychopathology (symptoms component scores), were established based on number of symptoms endorsed for each disorder assessed by the K-SADS-PL. Autistic and ADHD symptoms component scores were defined as the first component (describing 41% and 46%, respectively, of the variation in data) from a Multiple Correspondence Analysis (MCA) of the registered autistic and ADHD symptoms (R package: FactoMineR).(28) Further, parent-rated severity of ADHD symptoms and autistic traits were obtained with the ADHD-Rating Scale (ADHD-RS) and Social Responsiveness Scale 2 (SRS-2), respectively.(29–31) Research diagnoses based on all sources of clinical information were assigned according to the International Classification of Disorders 10$^{th}$ Revision (ICD-10).(32) ICD-10 diagnostic codes of autism assigned at the COPSYCH visit included the DF84.0, DF84.5 and DF84.8 diagnostic codes, and of ADHD DF90.0, DF90.8 and DF98.8.

## Statistical Analysis

We estimated the effect of maternal pre-intervention and post-intervention serum 25(OH)D as well as child serum 25(OH)D at age 6 months and 6 years on diagnosis of autism and ADHD and continuous autistic and ADHD symptoms component scores reflecting symptom load by logistic and linear regression analyses. The covariate adjusted association between maternal pre-intervention 25(OH)D and autistic symptom load was visualized in a partial residual plot. Covariates were included based on known risk factors for autism, ADHD, and known influencers of serum 25(OH)D (See Supplementary Methods). In analyses regarding maternal and child serum 25(OH)D and risk of autism and ADHD, we included all individuals attending the COPSYCH 10-year visit regardless of participation in the vitamin D3 trial.

Among COPSYCH participants included in the vitamin D3 trial, we estimated the effect of high-dose compared with standard-dose of vitamin D3 on the prevalence of autism and ADHD diagnoses and symptom load by logistic and linear regression analyses. We tested for interaction between pre-intervention serum 25(OH)D levels and the vitamin D3 intervention on psychopathological outcomes by adding cross-products to the models and performed analyses stratified according to maternal pre-intervention serum 25(OH)D at week 24 of pregnancy to assess the intervention effect according to early pregnancy 25(OH)D levels. Analyses were performed both crude and adjusted for pre-intervention pregnancy week 24 25(OH)D levels, season of birth, child sex, and n-3 LCPUFA intervention. In all analyses, we investigated for interaction with sex due to pre-existing studies suggesting sex differences in the effect of vitamin D on risk of psychopathology.(18,20,33)

To corroborate identified associations to K-SADS-PL diagnostic outcomes, we investigated the effect of maternal as well as child circulating 25(OH)D and the effect of the vitamin D3 intervention on the severity of parent-reported autistic traits and ADHD symptoms.

In all analyses, statistical significance was set as <0.05, 2-sided. Due to the relatively few individuals with missing information missing data was not imputed. We have not controlled for multiple testing since analyses were performed based on a strong hypothesis generated from existing research. Statistical analyses were performed using R statistical software version R4.2.1 (the R Foundation, Vienna). For complete overview of included exposure and outcome measures see Supplementary Figure 1.

# RESULTS

## Baseline characteristics

From the total COPSAC cohort including 700 mother-child pairs, 591 children were included in the COPSYCH 10-year visit and eligible for analyses on maternal and child serum 25(OH)D. For baseline characteristics of the COPSYCH 10-year visit see Supplementary Table 1.

From the total COPSAC cohort, a subgroup of 496 children participated both in the vitamin D3 trial and in the COPSYCH 10-year visit and were eligible for primary analyses on the intervention effect: 246 received high-dose and 250 standard-dose of vitamin D3 (Figure 1).

There were no significant differences in serum 25(OH)D at baseline or in season of birth between the intervention and the placebo group. Prior to the intervention, 51.4 % of mothers had levels of serum 25(OH)D ≥75nmol/L. Demographics are provided in Table 1. See the supplementary material for additional descriptive tables stratified according to outcome measures (Supplementary Tables 2-5).

In total, 74% of the mothers adhered to the intervention, which was defined as an intake of at least 80% of the prescribed capsules.(34,35) The safety profile of the RCT has been reported previously.(35)

## Serum 25(OH)D and risk of autism and ADHD

Of the total 591 individuals included in the COPSYCH visit, sixteen children (2.7%) were diagnosed with autism and 65 (11.0%) with ADHD. Clinically rated symptoms of autism were present in 49 individuals (8.3%) and of ADHD in 170 (28.8%). Adjusted analyses showed that higher maternal pre-intervention 25(OH)D level was associated with a decreased risk of autism (OR per 10 nmol/L 0.76 (0.59,0.97), p=0.034)), lower autistic symptom load (β per 10 nmol/L -0.03 (-0.05,0.00) p=0.024), and lower risk of ADHD diagnosis (OR per 10 nmol/L 0.88 (0.78,0.99), p=0.033), but not ADHD symptom load (β per 10 nmol/L -0.02 (-0.04,0.00) p=0.122) (See Supplementary Table 6). See Figure 2 for visualization of the effect of maternal pre-intervention 25(OH)D on autistic symptom load. Beta coefficients for all variables in adjusted models are provided in the supplementary Tables 7-10. We did not observe sex differences (p-interactions>0.05).

Maternal post-intervention serum 25(OH)D level or child level age 6 months or 6 years were not associated with autism or ADHD (Supplementary Table 11).

## High-dose vitamin D3 supplementation and risk of autism and ADHD

In the high-dose vitamin D3 supplementation group there were 5 (2.0%) children compared with 7 (2.8%) children in the standard-dose group diagnosed with autism at age 10. Clinically rated symptoms of autism were present in 15 (6.1%) in the high-dose group compared with 25 (10%) in the standard-dose group, ADHD diagnosis in 27 (11%) compared with 31 (12.4%), and clinically rated symptoms of ADHD in 67 (27.2%) compared with 76 (30.4%).

Vitamin D3 treatment group was not significantly associated with risk of autism (crude OR=0.72 (95% CI, 0.21,2.29) p=0.580), symptom load of autism (crude β=-0.08 (95% CI -0.19,0.03), p=0.142), ADHD diagnosis (crude OR 0.87 (95% CI 0.50,1.51) p=0.622), or symptom load of ADHD (crude β=-0.06 (95% CI -0.18,0.07) p=0.375) and there was no interaction with sex (Table 2). Results were unchanged after adjustments.

Within the high-dose vitamin D3 supplementation group, no children of mothers with pre-intervention 25(OH)D levels ≥75 nmol/L at week 24 (n=128) were diagnosed with autism as compared to 5 children of mothers with 25(OH)D <75 nmol/L (n=116), and there was a significant interaction between pre-intervention 25(OH)D levels and the vitamin D3 intervention on autism risk (interaction term coefficient = 0.97, crude p-interaction=0.030). Barnard's exact test inferred a significant protective effect of the vitamin D3 intervention on risk of autism within

mothers with pre-intervention 25(OH)D levels ≥75 nmol/L, OR=0, p=0.044. There was no significant interaction between pre-intervention 25(OH)D levels and the vitamin D3 intervention on autistic symptom load (crude p-interaction=0.261), ADHD diagnosis (crude p-interaction=0.687), or ADHD symptom load (crude p-interaction=0.703). (See Supplementary Methods, Supplementary Figure 2, and Supplementary Figure 3)

A threshold analysis (moving average) suggested a U-shape effect of the high-dose vitamin D3 intervention with a protective effect on autistic symptom load in cases of maternal pre-intervention 25(OH)D levels within the normal to high range of serum 25(OH)D (approximately 55-110 nmol/L) (Figure 3).

## Vitamin D and parent-rated autistic traits severity and ADHD symptoms

No significant associations were found between the vitamin D3 supplementation, maternal pre- or post-intervention or child serum 25(OH)D and parent-rated severity of autistic traits measured by SRS-2 or ADHD symptoms measured by ADHD-RS (Supplementary Table 12 (vitamin D3 intervention), Table 13 (maternal 25(OH)D), and Table 14 (child 25(OH)D)). However, estimates suggested lower SRS-total scores with increasing maternal pre-intervention 25(OH)D and child 6 months 25(OH)D levels.

## Sensitivity analyses

The association between maternal pre-intervention 25(OH)D and risk of ADHD disappeared after additional adjustment for maternal ADHD PRS (OR 0.94 (0.83,1.07), p=0.366). The association between higher maternal pre-intervention 25(OH)D and decreased autistic symptom load did replicate using alternative statistical models, however, results were insignificant. (see Supplementary Methods and Supplementary Tables 15-16)

# DISCUSSION

In this RCT, investigating the effect of high-dose (2800 IU/d) compared with standard-dose (400IU/d) of vitamin D3 from pregnancy week 24 until 1 week after birth, we found no overall protective effect on risk of autism, ADHD, or symptom loads. Higher maternal pre-intervention 25(OH)D was associated with a decreased risk of autism, lower autistic symptom load, and decreased risk of ADHD.

The present study overcomes important limitations of existing observational studies investigating the association between gestational serum 25(OH)D and risk of autism and ADHD in the offspring. First, the RCT design allows for an unbiased investigation of the effect of vitamin D3 supplementation in late pregnancy, a period characterized by rapid brain growth and neuronal development. This is of high importance due to the many known lifestyle factors influencing serum levels of vitamin D.(36) Second, this study was based on thorough clinical evaluations performed by uniformly trained nurses and medical doctors at the COPSAC research unit as opposed to parent-reported or registry-based outcomes more prone to bias.(37,38) Lastly,

consecutive follow-up and longitudinal deep phenotyping of the COPSAC2010 cohort allowed us to investigate the effects of serum 25(OH)D from the prenatal period until childhood controlling for potential confounders.

The study was limited by the low number of clinically evaluated cases of autism,(39) which could explain why, we found no overall intervention effect. A post hoc power calculation showed that the present study was underpowered (See Supplementary Results). Also, we are unable to determine whether a higher dose initiated earlier in pregnancy or even pre-pregnancy would have caused an effect. Further, the observational part of the study was limited by missing information on parental mental health status – an important potential confounder considering both autism and ADHD are highly heritable (heritability estimate for autism 74–93% and for ADHD 70-80%).(1,2) Analyses on the effect of maternal pre-intervention serum 25(OH)D adjusted for the mother's genetic risk of autism or ADHD removed the effect on ADHD (Supplementary Table 15). Lastly, the external validity of the present study is limited by the relatively high levels of maternal serum 25(OH)D when compared to global reports hereof.(3)

Regardless of the intervention, but with the risk of lifestyle confounding, we observed that higher maternal pre-intervention 25(OH)D was associated with a reduced risk of autism and ADHD and lower clinically evaluated symptom load of autism but not ADHD. However, this association with autistic symptoms was not significant using parent-reported autistic traits. Higher maternal serum 25(OH)D in pregnancy has previously been associated with lower risk of both autism and ADHD diagnosis.(9,11,13,14) The Generation R study reported an association between higher maternal gestational 25(OH)D and lower parent-rated autistic trait severity among offspring

334 measured by SRS-2 in a large cohort comprising 2866 mother-child pairs.(16) In a smaller case-
335 control study, higher gestational 25(OH)D was also associated with fewer autistic symptoms
336 measured by childhood autism rating scale (CARS) completed by health care
337 professionals.(7,40) Finally, a large birth-cohort study reported no association between
338 gestational 25(OH)D and later parent-reported symptoms of ADHD.(21)
339
340 The high-dose vitamin D3 supplementation during pregnancy was overall not protective of child
341 autism and ADHD diagnosis or symptom load. To our knowledge, no RCT has previously
342 investigated the effect of vitamin D supplementation in pregnancy on risk of autism or ADHD.
343 In a prospective study from 2016, vitamin D supplementation in pregnancy among mothers of
344 children with autism decreased the recurrence rate of autism in newborn siblings from previously
345 reported 20% to 5%.(41) These mothers were prescribed 5000 IU vitamin D3 per day during
346 pregnancy as opposed to 2800 IU/day in the present study. In the study newborns were also
347 supplemented with 1000 IU/day vitamin D until the age of three. A lower intervention dose of
348 vitamin D3 in our RCT may therefore to some extent explain the discrepancy with our results.
349
350 Among mothers with early pregnancy serum 25(OH)D ≥75 nmol/L, we found that the high-dose
351 vitamin D3 intervention may lower the risk of autism diagnosis. This may suggest that high
352 25(OH)D in early pregnancy is of particular importance for typical brain development. This is
353 supported by a large registry-based study showing an association between lower maternal serum
354 25(OH)D in first and early second trimester of pregnancy and increased risk of autism
355 diagnosis.(11) Furthermore, early pregnancy may represent a vulnerable phase since basics of the
356 neural system are established already during the embryonic stage.(42) Hence, it is plausible that

the vitamin D3 intervention in our study was introduced too late in pregnancy or that the intervention dose was too low to achieve an effect among mothers with vitamin D deficiency at randomization.

We performed a threshold analysis of the effect of the vitamin D3 supplementation on autistic symptom load according to maternal pre-intervention serum 25(OH)D. The analysis revealed a U-shaped association indicative of a protective effect of the vitamin D3 intervention among mothers with pre-intervention levels between approximately 55 to 110 nmol/L. U-shaped associations between vitamin D and bone health as well as aeroallergen sensitization have been described previously.(43,44) Further, a case-control study has also reported higher risk of schizophrenia among children with either low or high 25(OH)D measured in neonatal dried blood samples.(45) Future studies on vitamin D and autism should be aware of potential non-linear associations.

Two previous studies have reported sex-differences in the relationship between early life vitamin D status and autism, where one study reported a protective association of higher neonatal vitamin D only among girls(20) whereas another study reported a protective association of higher gestational vitamin D among boys and an opposite association among girls.(33) In our study, there was no interaction between sex and the intervention for neither autism nor ADHD.

Neither the suggested protective effect on autism diagnosis of the vitamin D3 intervention within mothers with early pregnancy levels of 25(OH)D ≥75nmol/L nor the protective association of higher gestational serum 25(OH)D on autistic symptom load could be replicated using the

parent-reported SRS-2. However, SRS-2 scores have been reported to be influenced by factors not specific to autism such as developmental difficulties and behavioral problems. Thus, SRS scores may to some extent reflect parent-evaluated general impairment of the child instead of the severity of core autistic traits.(38) Therefore, compared to a clinician rating of autistic symptoms, the SRS-2 may be a more unspecific measure of autistic trait severity, which may have prevented us from replicating our findings.

Finally, we found no associations of maternal post-intervention serum 25(OH)D or child serum 25(OH)D at either age 6 months or 6 years on risk of autism or ADHD, which contrasts a recent meta-analysis showing evidence of lower serum 25(OH)D in children and adolescents with autism.(46) However, all included studies were case-control and may be prone to bias from lifestyle factors such as picky eating patterns, less time spent outdoors, and medication influencing 25(OH)D levels,(46) factors which would probably not be as influential in childhood measurements. A meta-analysis from 2018 also suggested an association between low childhood 25(OH)D status and risk of ADHD(15), but a Mendelian randomization study did not find evidence of a causal relationship.(47)

In conclusion, higher maternal pre-intervention 25(OH)D was associated with a decreased risk of autism, lower autistic symptom load, and decreased risk of ADHD diagnosis. High-dose vitamin D3 supplementation from pregnancy week 24 until one week postpartum did not reduce overall risk of autism and ADHD diagnosis or symptom load in the offspring at age 10 compared to standard dose vitamin D3.

**Authors Contributions:** KA drafted the manuscript. All co-authors (JRMJ, AS, DH, RV, JBR, NB, AE, PM, NF, MH, BF, BYG, MAR, NB, JS, KB, BHE, BC) have provided important intellectual input and contributed considerably to the analyses and interpretation of the data. All authors guarantee that the accuracy and integrity of any part of the work have been appropriately investigated and resolved and all have approved the final version of the manuscript. The corresponding author had full access to the data and had final responsibility for the decision to submit for publication. No honorarium, grant, or other form of payment was given to any of the authors to produce this manuscript.

**Source of Funding:** All funding received by COPSAC is listed on www.copsac.com. The Lundbeck Foundation (Grant no R16-A1694); The Ministry of Health (Grant no 903516); Danish Council for Strategic Research (Grant no 0603-00280B) and The Capital Region Research Foundation have provided core support to the COPSAC research centre. This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No. 946228) (BC).

**Conflict of interest:** B.H.E. is part of the Advisory Board of Eli Lilly Denmark A/S, Janssen-Cilag, Lundbeck Pharma A/S, and Takeda Pharmaceutical Company Ltd; and has received lecture fees from Bristol-Myers Squibb, Boehringer Ingelheim, Otsuka Pharma Scandinavia AB, Eli Lilly Company, and Lundbeck Pharma A/S. BG has been the leader of a Lundbeck Foundation Centre of Excellence for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS) (January 2009 – December 2021), which was partially financed by an independent grant from the Lundbeck Foundation based on international review and partially

financed by the Mental Health Services in the Capital Region of Denmark, the University of Copenhagen, and other foundations. All grants are the property of the Mental Health Services in the Capital Region of Denmark and administrated by them. She has no other conflicts to disclose. Remaining authors declare no potential, perceived, or real conflict of interest regarding the content of this manuscript. The funding agencies did not have any role in design and conduct of the study; collection, management, and interpretation of the data; or preparation, review, or approval of the manuscript. No pharmaceutical company was involved in the study.

**Governance:** We are aware of and comply with recognized codes of good research practice, including the Danish Code of Conduct for Research Integrity. We comply with national and international rules on the safety and rights of patients and healthy subjects, including Good Clinical Practice (GCP) as defined in the EU's Directive on Good Clinical Practice, the International Conference on Harmonisation's (ICH) good clinical practice guidelines and the Helsinki Declaration. Privacy is important to us which is why we follow national and international legislation on General Data Protection Regulation (GDPR), the Danish Act on Processing of Personal Data and the practice of the Danish Data Inspectorate.

**Acknowledgements:** We express our deepest gratitude to the children and families of the COPSAC2010 cohort study for all their support and commitment. We acknowledge and appreciate the unique efforts of the COPSAC research team. We would like to acknowledge the huge work of late professor Hans Bisgaard, who was the founder of COPSAC and was head of the clinical research center for more than 25 years. Hans was a dedicated, innovative physician-scientist who pushed the asthma research field forward. He contributed immensely to pediatric

research through the COPSAC birth cohorts, as well as a vast amount of other clinical studies on childhood asthma. Hans's impressive work and ideas live on in the following studies conducted in the birth cohort. Thank you for being a great inspiration to us all.

# References


1. Lord C, Elsabbagh M, Baird G, Veenstra-Vanderweele J. Autism spectrum disorder. The Lancet 2018;392:508–20.

2. Posner J, Polanczyk GV, Sonuga-Barke E. Attention-deficit hyperactivity disorder. The Lancet 2020;395:450–62.

3. Saraf R, Morton SMB, Camargo CA, Grant CC. Global summary of maternal and newborn vitamin D status - a systematic review: Global maternal and newborn vitamin D status. Matern Child Nutr 2016;12:647–68.

4. Groves NJ, McGrath JJ, Burne THJ. Vitamin D as a Neurosteroid Affecting the Developing and Adult Brain. Annu Rev Nutr 2014;34:117–41.

5. Ali A, Cui X, Eyles D. Developmental vitamin D deficiency and autism: Putative pathogenic mechanisms. J Steroid Biochem Mol Biol 2018;175:108–18.

6. Pet MA, Brouwer-Brolsma EM. The Impact of Maternal Vitamin D Status on Offspring Brain Development and Function: a Systematic Review. Adv Nutr Int Rev J 2016;7:665–78.

7. Chen J, Xin K, Wei J, Zhang K, Xiao H. Lower maternal serum 25(OH) D in first trimester associated with higher autism risk in Chinese offspring. J Psychosom Res 2016;89:98–101.

8. Morales E, Julvez J, Torrent M, Ballester F, Rodríguez-Bernal CL, Andiarena A, Vegas O, Castilla AM, Rodriguez-Dehli C, Tardón A, et al. Vitamin D in Pregnancy and Attention Deficit Hyperactivity Disorder-like Symptoms in Childhood: Epidemiology 2015;26:458–65.

9. Vinkhuyzen AAE, Eyles DW, Burne THJ, Blanken LME, Kruithof CJ, Verhulst F, White T, Jaddoe VW, Tiemeier H, McGrath JJ. Gestational vitamin D deficiency and autism spectrum disorder. BJPsych Open 2017;3:85–90.

10. Lee BK, Eyles DW, Magnusson C, Newschaffer CJ, McGrath JJ, Kvaskoff D, Ko P, Dalman C, Karlsson H, Gardner RM. Developmental vitamin D and autism spectrum disorders: findings from the Stockholm Youth Cohort. Mol Psychiatry 2021;26:1578–88.

11. Sourander A, Upadhyaya S, Surcel H-M, Hinkka-Yli-Salomäki S, Cheslack-Postava K, Silwal S, Sucksdorff M, McKeague IW, Brown AS. Maternal Vitamin D Levels During Pregnancy and Offspring Autism Spectrum Disorder. Biol Psychiatry 2021;90:790–7.

12. Magnusson C, Kosidou K, Dalman C, Lundberg M, Lee BK, Rai D, Karlsson H, Gardner R, Arver S. Maternal vitamin D deficiency and the risk of autism spectrum disorders: population-based study. BJPsych Open 2016;2:170–2.

13. Chu SH, Huang M, Kelly RS, Kachroo P, Litonjua AA, Weiss ST, Lasky-Su J. Circulating levels of maternal vitamin D and risk of ADHD in offspring: results from the Vitamin D Antenatal Asthma Reduction Trial. Int J Epidemiol 2021;dyab194.

14. Sucksdorff M, Brown AS, Chudal R, Surcel H-M, Hinkka-Yli-Salomäki S, Cheslack-Postava K, Gyllenberg D, Sourander A. Maternal Vitamin D Levels and the Risk of Offspring Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 2021;60:142-151.e2.

15. Khoshbakht Y, Bidaki R, Salehi-Abargouei A. Vitamin D Status and Attention Deficit Hyperactivity Disorder: A Systematic Review and Meta-Analysis of Observational Studies. Adv Nutr 2018;9:9–20.

16. Vinkhuyzen AAE, Eyles DW, Burne THJ, Blanken LME, Kruithof CJ, Verhulst F, Jaddoe VW, Tiemeier H, McGrath JJ. Gestational vitamin D deficiency and autism-related traits: the Generation R Study. Mol Psychiatry 2018;23:240–6.

17. Whitehouse AJO, Holt BJ, Serralha M, Holt PG, Hart PH, Kusel MMH. Maternal Vitamin D Levels and the Autism Phenotype Among Offspring. J Autism Dev Disord 2013;43:1495–504.

18. Daraki V, Roumeliotaki T, Koutra K, Chalkiadaki G, Katrinaki M, Kyriklaki A, Kampouri M, Margetaki K, Vafeiadi M, Papavasiliou S, et al. High maternal vitamin D levels in early pregnancy may protect against behavioral difficulties at preschool age: the Rhea mother–child cohort, Crete, Greece. Eur Child Adolesc Psychiatry 2018;27:79–88.

19. Mossin MH, Aaby JB, Dalgård C, Lykkedegn S, Christesen HT, Bilenberg N. Inverse associations between cord vitamin D and attention deficit hyperactivity disorder symptoms: A child cohort study. Aust N Z J Psychiatry 2017;51:703–10.

20. Schmidt RJ, Niu Q, Eyles DW, Hansen RL, Iosif A. Neonatal vitamin D status in relation to autism spectrum disorder and developmental delay in the CHARGE case–control study. Autism Res 2019;12:976–88.

21. López-Vicente M, Sunyer J, Lertxundi N, González L, Rodríguez-Dehli C, Espada Sáenz-Torre M, Vrijheid M, Tardón A, Llop S, Torrent M, et al. Maternal circulating Vitamin D3 levels during pregnancy and behaviour across childhood. Sci Rep 2019;9:14792.

22. Gustafsson P, Rylander L, Lindh CH, Jönsson BAG, Ode A, Olofsson P, Ivarsson SA, Rignell-Hydbom A, Haglund N, Källén K. Vitamin D Status at Birth and Future Risk of Attention Deficit/Hyperactivity Disorder (ADHD). Reif A, editor. PLOS ONE 2015;10:e0140164.

23. Strøm M, Halldorsson TI, Hansen S, Granström C, Maslova E, Petersen SB, Cohen AS, Olsen SF. Vitamin D Measured in Maternal Serum and Offspring Neurodevelopmental Outcomes: A Prospective Study with Long-Term Follow-Up. Ann Nutr Metab 2014;64:254–61.

24. Mohammadzadeh P, Rosenberg JB, Vinding R, Møllegaard Jepsen JR, Lindberg U, Følsgaard N, Erlang Sørensen M, Sulaiman D, Bilenberg N, Mitta Raghava J, et al. Effects of prenatal nutrient supplementation and early life exposures on neurodevelopment at age 10: a randomised controlled trial - the COPSYCH study protocol. BMJ Open 2022;12:e047706.

25. Bisgaard H, Vissing NH, Carson CG, Bischoff AL, Følsgaard NV, Kreiner-Møller E, Chawes BLK, Stokholm J, Pedersen L, Bjarnadóttir E, et al. Deep phenotyping of the unselected COPSAC2010 birth cohort study. Clin Exp Allergy J Br Soc Allergy Clin Immunol 2013;43:1384–94.

26. Brustad N, Fink NR, Stokholm J, Bønnelykke K, Følsgaard NV, Hougaard D, Brix S, Lasky-Su J, Weiss ST, Chawes B. Associations of 25 Hydroxyvitamin D and High Sensitivity C-reactive Protein Levels in Early Life. Nutrients 2021;14:15.

27. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial Reliability and Validity Data. J Am Acad Child Adolesc Psychiatry 1997;36:980–8.

28. Lê S, Josse J, Husson F. **FactoMineR** : An *R* Package for Multivariate Analysis. J Stat Softw [Internet] 2008 [cited 2022 Dec 5];25. Available from: http://www.jstatsoft.org/v25/i01/

29. Constantino JN. Social responsiveness scale: SRS-2. Western Psychological Services Torrance, CA; 2012.

30. Constantino JN, Davis SA, Todd RD, Schindler MK, Gross MM, Brophy SL, Metzger LM, Shoushtari CS, Splinter R, Reich W. Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised. J Autism Dev Disord 2003;33:427–33.

31. Makransky G, Bilenberg N. Psychometric properties of the parent and teacher ADHD Rating Scale (ADHD-RS): measurement invariance across gender, age, and informant. Assessment United States; 2014;21:694–705.

32. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. World Health Organization [Internet] 1992; Available from: https://cdn.who.int/media/docs/default-source/classification/other-classifications/9241544228_eng.pdf

33. Windham GC, Pearl M, Poon V, Berger K, Soriano JW, Eyles D, Lyall K, Kharrazi M, Croen LA. Maternal Vitamin D Levels During Pregnancy in Association With Autism Spectrum Disorders ( ASD ) or Intellectual Disability ( ID ) in Offspring; Exploring Non-linear Patterns and Demographic Sub-groups. Autism Res 2020;13:2216–29.

34. Sass L, Vinding RK, Stokholm J, Bjarnadóttir E, Noergaard S, Thorsen J, Sunde RB, McGrath J, Bønnelykke K, Chawes B, et al. High-Dose Vitamin D Supplementation in Pregnancy and Neurodevelopment in Childhood: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open 2020;3:e2026018.

35. Chawes BL, Bønnelykke K, Stokholm J, Vissing NH, Bjarnadóttir E, Schoos A-MM, Wolsk HM, Pedersen TM, Vinding RK, Thorsteinsdóttir S, et al. Effect of Vitamin $D_3$ Supplementation During Pregnancy on Risk of Persistent Wheeze in the Offspring: A Randomized Clinical Trial. JAMA 2016;315:353.

36. Mena-Bravo A, Calderón-Santiago M, Lope V, Kogevinas M, Pollán M, Luque de Castro MD, Priego-Capote F. Vitamin D3 levels in women and factors contributing to explain metabolic variations. J Steroid Biochem Mol Biol 2021;211:105884.

37. Mohr-Jensen C, Vinkel Koch S, Briciet Lauritsen M, Steinhausen H-C. The validity and reliability of the diagnosis of hyperkinetic disorders in the Danish Psychiatric Central Research Registry. Eur Psychiatry 2016;35:16–24.

38. Hus V, Bishop S, Gotham K, Huerta M, Lord C. Factors influencing scores on the social responsiveness scale: Factors influencing the SRS. J Child Psychol Psychiatry 2013;54:216–24.

39. Gregersen M, Søndergaard A, Brandt JM, Ellersgaard D, Rohd SB, Hjorthøj C, Ohland J, Krantz MF, Wilms M, Andreassen AK, et al. Mental disorders in preadolescent children at familial high-risk of schizophrenia or bipolar disorder – a four-year follow-up study: The Danish High Risk and Resilience Study, VIA 11. J Child Psychol Psychiatry 2022;63:1046–56.

40. Chen K-L, Lin C-H, Yu T-Y, Huang C-Y, Chen Y-D. Differences Between the Childhood Autism Rating Scale and the Social Responsiveness Scale in Assessing Symptoms of Children with Autistic Spectrum Disorder. J Autism Dev Disord 2018;48:3191–8.

41. Stubbs G, Henley K, Green J. Autism: Will vitamin D supplementation during pregnancy and early childhood reduce the recurrence rate of autism in newborn siblings? Med Hypotheses 2016;88:74–8.

42. Konkel L. The Brain before Birth: Using fMRI to Explore the Secrets of Fetal Neurodevelopment. Environ Health Perspect 2018;126:112001.

43. Anagnostis P, Bosdou JK, Kenanidis E, Potoupnis M, Tsiridis E, Goulis DG. Vitamin D supplementation and fracture risk: Evidence for a U-shaped effect. Maturitas 2020;141:63–70.

44. Rothers J, Wright AL, Stern DA, Halonen M, Camargo CA. Cord blood 25-hydroxyvitamin D levels are associated with aeroallergen sensitization in children from Tucson, Arizona. J Allergy Clin Immunol 2011;128:1093-1099.e5.

45. Eyles DW, Trzaskowski M, Vinkhuyzen AAE, Mattheisen M, Meier S, Gooch H, Anggono V, Cui X, Tan MC, Burne THJ, et al. The association between neonatal vitamin D status and risk of schizophrenia. Sci Rep 2018;8:17692.

46. Wang Z, Ding R, Wang J. The Association between Vitamin D Status and Autism Spectrum Disorder (ASD): A Systematic Review and Meta-Analysis. Nutrients 2020;13:86.

47. Libuda L, Naaresh R, Ludwig C, Laabs B-H, Antel J, Föcker M, Hebebrand J, Hinney A, Peters T. A mendelian randomization study on causal effects of 25(OH)vitamin D levels on attention deficit/hyperactivity disorder. Eur J Nutr 2021;60:2581–91.

# Tables

**Table 1.** Baseline characterization of participants of the vitamin D3 RCT included in the COPSYCH project

| Stratified by participation in the vitamin D3 RCT | All | Placebo | Vitamin D3 |
|---|---|---|---|
| | n = 496 | n = 250 | n = 246 |
| Diagnosis of autism, n (%) | 12 (2.4) | 7 (2.8) | 5 (2.0) |
| Individuals presenting clinically rated symptoms of autism, n (%) | 40 (8.1) | 25 (10.0) | 15 (6.1) |
| Diagnosis of ADHD, n (%) | 58 (11.7) | 31 (12.4) | 27 (11.0) |
| Individuals presenting clinically rated symptoms of ADHD, n (%) | 143 (28.8) | 76 (30.4) | 67 (27.2) |
| Long chain n-3 LPUFA supplementation, n (%) | 249 (50.2) | 122 (48.8) | 127 (51.6) |
| Maternal pre-intervention 25(OH)D, nmol/L, (mean (SD)) | 75.81 (25.66) | 75.57 (25.44) | 76.05 (25.92) |
| Maternal pre-intervention 25(OH)D,≥75 nmol/L, n (%) | 253 (51.4) | 125 (50.4) | 128 (52.5) |
| Maternal post-intervention 25(OH)D, nmol/L, (mean (SD)) | 89.99 (38.09) | 71.86 (31.54) | 108.33 (35.31) |
| Maternal post-intervention 25(OH)D,≥75 nmol/L, n (%) | 313 (64.0) | 108 (43.9) | 205 (84.4) |
| Maternal age at childbirth, years (mean (SD)) | 32.33 (4.28) | 31.98 (4.24) | 32.69 (4.30) |
| Maternal pre-pregnancy weight, kg, (mean (SD)) | 69.17 (13.57) | 69.15 (13.18) | 69.19 (13.99) |
| Parity | | | |
| 1, n (%) | 219 (44.2) | 123 (49.2) | 96 (39.0) |
| 2, n (%) | 198 (39.9) | 91 (36.4) | 107 (43.5) |
| ≥3, n (%) | 79 (15.9) | 36 (14.4) | 43 (17.5) |
| Alcohol intake in pregnancy, n (%) | 81 (16.4) | 39 (15.6) | 42 (17.1) |
| Smoking third trimester, n (%) | 17 (3.4) | 11 (4.4) | 6 (2.4) |
| Exclusive lactation, weeks (median [IQR]) | 17.43 [8.57, 21.57] | 17.57 [8.93, 21.68] | 17.43 [8.29, 21.39] |
| Maternal educational level (%) | | | |
| Low (Elementary school or college graduate) | 41 (8.3) | 24 (9.6) | 17 (6.9) |
| Medium (Tradesman certification or bachelor's degree) | 314 (63.3) | 162 (64.8) | 152 (61.8) |
| High (Master's degree or higher) | 141 (28.4) | 64 (25.6) | 77 (31.3) |
| Household income (%) | | | |
| Low (< 100.000DKK[1]) | 44 (8.9) | 23 (9.2) | 21 (8.5) |
| Medium (100.000-200.000 DKK) | 257 (51.8) | 134 (53.6) | 123 (50.0) |
| High (> 200.000 DKK) | 195 (39.3) | 93 (37.2) | 102 (41.5) |
| Fathers age, years, (mean (SD)) | 34.63 (5.19) | 34.29 (5.20) | 34.98 (5.17) |
| Gestational age, days (mean (SD)) | 279.43 (10.86) | 279.32 (10.25) | 279.54 (11.46) |
| Season of birth | | | |
| Winter, n (%) | 179 (36.1) | 87 (34.8) | 92 (37.4) |
| Spring, n (%) | 97 (19.6) | 50 (20.0) | 47 (19.1) |
| Summer, n (%) | 100 (20.2) | 50 (20.0) | 50 (20.3) |
| Fall, n (%) | 120 (24.2) | 63 (25.2) | 57 (23.2) |
| Sex, male, n (%) | 256 (51.6) | 123 (49.2) | 133 (54.1) |
| Race, White, n (%) | 475 (95.8) | 240 (96.0) | 235 (95.5) |

Abbreviations: ADHD = Attention Deficit Hyperactivity Disorder. RCT = Randomized controlled trial. SD = standard deviation. IQR = interquartile range. N = number.
SI Conversion: vitamin D can be converted to ng/mL by dividing by 2.496. [1] DKK = 0.14 USD.
Alcohol intake in pregnancy describes any intake of alcohol during pregnancy, yes/no.
Smoking in third trimester describes any smoking in third trimester of pregnancy, yes/no.
Information on race was obtained through parental interviews and was defined as either white or non-white.

650
651

| Table 2: Vitamin D3 supplementation and K-SADS-PL evaluation of autism and ADHD | | | | |
|---|---|---|---|---|
| K-SADS-PL measure | N (N cases) | Odds Ratio Estimate (CI) | N (N cases) | Odds Ratio Estimate (CI) Adjusted[1] |
| Autism | 496 (12) | 0.72 (0.21,2.29) | 492 (12) | 0.72 (0.21,2.32) |
| ADHD | 496 (58) | 0.87 (0.50,1.51) | 492 (57) | 0.87 (0.49,1.53) |
| K-SADS-PL measure | N | Beta Estimate (CI) | N | Beta Estimate (CI) Adjusted[1] |
| Autistic symptoms component score | 496 | -0.08 (-0.19,0.03) | 492 | -0.08 (-0.19,0.03) |
| ADHD symptoms component score | 496 | -0.06 (-0.18,0.07) | 492 | -0.07 (-0.19,0.05) |

[1]Adjusted for week 24 vitamin D levels, season of birth, child sex, and the n-3 LCPUFA intervention.
ADHD = attention deficit hyperactivity disorder. CI: confidence interval. K-SADS-PL = Kiddie-Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version. N = number.

ICD-10 diagnostic codes of Autism assigned at the COPSYCH visit included the DF84.0, DF84.5 and DF84.8 diagnostic codes, and of ADHD DF90.0, DF90.8 and DF98.8.

652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672

# Figure legends

**Figure 1:** CONSORT Participant flow diagram

**Figure 2: Partial residual plot of the covariate adjusted linear association between maternal pre-intervention pregnancy week 24 25(OH)D and autistic symptom load measured by K-SADS-PL among 569 individuals**

The linear fit is represented by the broken blue line and a smooth (loess) of the partial residuals by a solid magenta line (R package: crPlots). Adjusted for child sex, birth weight, gestational age, season of week 24 25(OH)D measurement, social circumstances, maternal smoking in third trimester of pregnancy, maternal pre-pregnancy weight, and fathers´ age. The study population included all individuals included in the COPSAC2010 cohort with available measurements of 25(OH)D in pregnancy week 24 and with offspring participating in the COPSYCH visit at age 10 regardless of participation in the vitamin D3 trial.

**Figure 3: Threshold analysis of the effect of high-dose vitamin D3 supplementation on autistic symptom load measured by K-SADS-PL according to maternal pre-intervention serum 25(OH)D measured at pregnancy week 24**

Overall sample size was 492 individuals. The violin plot below shows the distribution of the measured maternal pre-intervention serum 25(OH)D. Linear regression was used to estimate the effect of the intervention according to maternal pre-intervention 25(OH)D within a moving window of ± 20 nmol/L. Black line marks the beta estimate and grey area the corresponding 95% confidence interval. Estimates are unadjusted.







**Declaration of interests**

☐ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☒ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Klaus Boennelykke reports financial support was provided by The Lundbeck Foundation. Klaus Boennelykke reports was provided by The Ministry of Health (Denmark). Klaus Boennelykke reports financial support was provided by Danish Council for Strategic Research. Klaus Boennelykke reports financial support was provided by The Capital Region Research Foundation (Denmark). Bo Chawes reports financial support was provided by European Research Council. Bjoern Ebdrup reports a relationship with Eli Lilly Denmark that includes: board membership. B.H.E. is part of the Advisory Board of Eli Lilly Denmark A/S, Janssen-Cilag, Lundbeck Pharma A/S, and Takeda Pharmaceutical Company Ltd; and has received lecture fees from Bristol-Myers Squibb, Boehringer Ingelheim, Otsuka Pharma Scandinavia AB, Eli Lilly Company, and Lundbeck Pharma A/S. BG has been the leader of a Lundbeck Foundation Centre of Excellence for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS) (January 2009 – December 2021), which was partially financed by an independent grant from the Lundbeck Foundation based on international review and partially financed by the Mental Health Services in the Capital Region of Denmark, the University of Copenhagen, and other foundations. All grants are the property of the Mental Health Services in the Capital Region of Denmark and administrated by them. She has no other conflicts to disclose. Remaining authors declare no potential, perceived, or real conflict of interest regarding the content of this manuscript. The funding agencies did not have any role in design and conduct of the study; collection, management, and interpretation of the data; or preparation, review, or approval of the manuscript. No pharmaceutical company was involved in the study.